COMMUNIQUÉS West-GlobeNewswire

TG Therapeutics Announces Initiation of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial in Follicular Lymphoma
27/11/2017
NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics (NASDAQ: TGTX ) announced today that along with SWOG, the global cancer clinical trials group funded by the National Cancer Institute (NCI), it has initiated a [...]
Forward Pharma to Participate in Investor Conferences in December
27/11/2017
COPENHAGEN, Denmark, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ: FWP ) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in two [...]
The Joint Corp. to Present at the 6th Annual Roth Utah Active & Healthy Lifestyle Corp Access Event
27/11/2017
SCOTTSDALE, Ariz., Nov. 27, 2017 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT ), a national operator, manager and franchisor of chiropractic clinics, announced it will conduct one-on-one meetings at the 6 th Annual [...]
Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development
27/11/2017
NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]
Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference
27/11/2017
Continued to Demonstrate Improvement across all Key Fabry Disease Parameters at 24 Months Low Incidence of Treatment Induced Anti-Drug Antibodies which Reversed Entirely Following 12 Months of Treatment without [...]
GW Pharmaceuticals to Report Q4 and Year-End Financial Results and Host Conference Call on 4 December, 2017
27/11/2017
LONDON, Nov. 27, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its [...]
Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome
27/11/2017
-- Treatment with Firdapse Achieved Statistical Significance for Co-Primary Endpoints and Secondary Endpoint -- -- Positive Results to Support Planned NDA Submission in the First Quarter of 2018 -- -- Conference Call [...]
ContraVir Pharmaceuticals to Make Three Presentations at HEP DART 2017
27/11/2017
EDISON, N.J., Nov. 27, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced [...]
INSYS Therapeutics, Inc. to Participate in the 29th Annual Piper Jaffray Healthcare Conference
27/11/2017
PHOENIX, Nov. 27, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY ) (“INSYS” or “the company”) announced today that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial [...]
GENFIT: Contributing Significantly to the European LITMUS Initiative on NASH Biomarkers
27/11/2017
GENFIT: Contributing Significantly to the European LITMUS Initiative on NASH Biomarkers GENFIT significantly contributes to LITMUS (The "Liver Investigation: Testing Marker Utility in Steatohepatitis" consortium), by [...]
GENFIT : Contribution significative à l'initiative européenne LITMUS sur les biomarqueurs NASH
27/11/2017
GENFIT : Contribution significative à l'initiative européenne LITMUS sur les biomarqueurs NASH GENFIT contribue de manière significative au consortium LITMUS (« Liver Investigation: Testing Marker Utility in [...]
Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
27/11/2017
New data showed switching moderate-to-severe, symptomatic COPD patients from Seretide ® * to Ultibro ® Breezhaler ® improved lung function and was well tolerated. The FLASH study is the first randomized controlled trial [...]
EnvoyAI launches with 35 algorithms contributed by 14 newly-contracted artificial intelligence development partners
26/11/2017
CAMBRIDGE, Mass., Nov. 26, 2017 (GLOBE NEWSWIRE) -- Artificial intelligence platform provider, EnvoyAI ( www.envoyai.com ) today announced the launch of the EnvoyAI Exchange, a platform described by AuntMinnie as the " [...]
Vital to Unveil Newest Vitrea® Advanced Visualization Release at RSNA 2017: Building Excellence for the Future
25/11/2017
MINNETONKA, Minn., Nov. 25, 2017 (GLOBE NEWSWIRE) -- Vital Images ® unveils the newest version of Vitrea Advanced Visualization software, which is the cornerstone of its imaging platform. This includes numerous product [...]
University of Utah Health Extends 3D Printing to Physicians with TeraRecon
25/11/2017
FOSTER CITY, Calif., Nov. 25, 2017 (GLOBE NEWSWIRE) -- University of Utah Hospitals & Clinics ( healthcare.utah.edu ), together with TeraRecon ( www.terarecon.com ), the market leading advanced visualization [...]
JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix
24/11/2017
Leuven (Belgium) - November 24, 2017, 22:00h CEST -TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding [...]
VANC Pharmaceuticals Plans to Launch INSTI HIV Test with United Pharma Group on World AIDS Day
24/11/2017
VANCOUVER, British Columbia, Nov. 24, 2017 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. ( “VANC” or the “Company” ) (TSXV:VANC) (OTCQB:NUVPF) announces today the intention to launch the INSTI HIV rapid point-of-care [...]
Orphazyme A/S: Stabilisation measures taken
24/11/2017
Company announcement No. 14/2017 Orphazyme A/S Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 24 November 2017 NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN [...]
Misonix, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference
24/11/2017
FARMINGDALE, N.Y., Nov. 24, 2017 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON ), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today that Stavros [...]

Pages